Repurposed drug may help stabilize vision in rare disease

Raj Apte, MD, PhD, and medical student Wilson Wang, see a patient for RVCL-S, a rare neurological disease that affects small blood vessels, at the Center for Outpatient Health, on May 23, 2024. Wilson is first author on a phase two clinical trial with Apte. MATT MILLER/WASHINGTON UNIVERSITY SCHOOL OF MEDICINE

Ophthalmologist Rajendra S. Apte, MD, PhD, (right), of Washington University School of Medicine in St. Louis, examines patient Patricia Collins (left) while medical student Wilson Wang observes. Collins is a participant in a clinical trial that tests the safety and efficacy of an FDA-approved drug in stabilizing vision in patients with RVCL-S, a rare genetic disease that affects tiny blood vessels in the body.